课题基金 / 基金详情

Randomised Controlled Trial of 6-Mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgic

Randomised Controlled Trial of 6-Mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgic
6-巯基嘌呤与安慰剂预防手术后克罗恩病复发的随机对照试验
批准号:
G0600329/1
负责人:
Jack Satsangi
金额:
$188.51万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2007
资助国家:
英国
项目状态:
已结题
起止时间:
2007 至 --

项目摘要

项目成果

Jack Satsangi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Crohn s disease is a chronic disabling condition affecting the bowel. Although medical treatment is effective approximately 50% of patient will need an operation to remove an affected segment of bowel over the first 5 years after diagnosis. Recurrence following surgery occurs in the majority of patients. 6-Mercaptopurine is an effective treatment for the reduction of symptoms and maintenance of well being in Crohn s disease but its use to prevent post operative recurrence is poorly defined. Previous studies have been small, retrospective or flawed in design. In this multicentre study we wish to assess the value of the drug 6-mercaptopurine to prevent recurrence of Crohn s disease following surgery. We will use the recurrence of symptoms as the primary outcome measure, with endoscopic examination of the relevant area and the need for further sugery as secondary outcome measures. If this trial were to show an effect of the drug we would anticipate a wide uptake and improved quality of life for patients with Crohn s disease following surgery.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Evaluating the importance of autophagy/xenophagy in protecting the intestinal epithelium in Crohn s Disease
  • 批准号:
    G0800759/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $42.11万
  • 财政年份:
    2009
  • 负责人:
    Jack Satsangi
  • 依托单位:
海外基金